Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003288 · ClinicalTrials.gov registry record · Phase 1
Tirapazamine Plus Cyclophosphamide in Treating Children With Refractory Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00003288: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00003288 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003288, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
Phase I trial to study the effectiveness of tirapazamine plus cyclophosphamide in treating children who have refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL filgrastim
- DRUG tirapazamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 1998-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003288
The ClinicalTrials.gov registry entry for NCT00003288 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cyclophosphamide is the first listed.
NCT00003288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003288 about?
NCT00003288 is a clinical study titled "Tirapazamine Plus Cyclophosphamide in Treating Children With Refractory Solid Tumors". Phase I trial to study the effectiveness of tirapazamine plus cyclophosphamide in treating children who have refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
What is the current status of trial NCT00003288?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 1998-08.
What interventions are being tested in trial NCT00003288?
The interventions under investigation include: cyclophosphamide (DRUG), filgrastim (BIOLOGICAL), tirapazamine (DRUG).
Who is sponsoring clinical trial NCT00003288?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.